Evidence map›Paper›PMID 39713469›Full record

ArticlebioRxiv : the preprint server for biology2025

Behavioral and genetic markers of susceptibility to escalate fentanyl intake.

Jack Keady, Richard Charnigo, Jakob D Shaykin, Emily R Prantzalos, Mengfan Xia, Emily Denehy, Cody Bumgardner, Justin Miller, Pavel Ortinski, Michael T Bardo and 1 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Jack KeadyCollege of Pharmacy, University of Kentucky, University of Kentucky, Lexington, KY 40506, USA.
Richard CharnigoSanders-Brown Center on Aging, University of Kentucky, Lexington, KY 40506, USA.
Jakob D ShaykinCollege of Pharmacy, University of Kentucky, University of Kentucky, Lexington, KY 40506, USA.
Emily R PrantzalosCollege of Pharmacy, University of Kentucky, University of Kentucky, Lexington, KY 40506, USA.
Mengfan XiaDepartment of Neuroscience, University of Kentucky, University of Kentucky, Lexington, KY 40506, USA.
Emily DenehyDepartment of Psychology, University of Kentucky, University of Kentucky, Lexington, KY 40506, USA.
Cody BumgardnerDepartment of Pathology and Laboratory Medicine, University of Kentucky, Lexington, KY 40506, USA.
Justin MillerDepartment of Pathology and Laboratory Medicine, University of Kentucky, Lexington, KY 40506, USA.ORCID 0000-0002-5309-1570
Pavel OrtinskiDepartment of Neuroscience, University of Kentucky, University of Kentucky, Lexington, KY 40506, USA.
Michael T BardoDepartment of Psychology, University of Kentucky, University of Kentucky, Lexington, KY 40506, USA.
Jill R TurnerCollege of Pharmacy, University of Kentucky, University of Kentucky, Lexington, KY 40506, USA.

Funding

University of Kentucky Alzheimer's Disease Research CenterP30AG072946 · NIA · UNIVERSITY OF KENTUCKY · PI Erin Abner · 2021 to 2026
$23.5M
Research Training in Drug Abuse BehaviorT32DA035200 · NIDA · UNIVERSITY OF KENTUCKY · PI CRAIG R RUSH, William Walton Stoops · 2013 to 2026
$4.4M
Functional and Genomic Signatures of Escalated Fentanyl UseR01DA053070 · NIDA · UNIVERSITY OF KENTUCKY · PI BARDO, MICHAEL T, ORTINSKI, PAVEL IVANOVICH · 2021 to 2025
$3.2M
Development of Agents for Synthetic Opioid OverdoseU01DA051377 · NIDA · UNIVERSITY OF KENTUCKY · PI PRISINZANO, THOMAS EDWARD · 2021 to 2023
$1.4M
Role of Dynamic Signaling of NRG3-ErbB4 in the Prefrontal Cortex in Mediating Nicotine Withdrawal PhenotypesF31DA057812 · NIDA · UNIVERSITY OF KENTUCKY · PI PRANTZALOS, EMILY · 2024 to 2025
$97k
NIA NIH HHS P30 AG072946NIDA NIH HHS F31 DA057812NIDA NIH HHS R01 DA053070NIDA NIH HHS T32 DA035200NIDA NIH HHS U01 DA051377
6 · The paper itself

Abstract

Background: The "loss of control" over drug consumption, present in opioid use disorder (OUD) and known as escalation of intake, is well-established in preclinical rodent models. However, little is known about how antecedent behavioral characteristics, such as valuation of hedonic reinforcers prior to drug use, may impact the trajectory of fentanyl intake over time. Moreover, it is unclear if distinct escalation phenotypes may be driven by genetic markers predictive of OUD susceptibility. Methods: Male and female Sprague-Dawley rats (n=63) were trained in a sucrose reinforcement task using a progressive ratio schedule. Individual differences in responsivity to sucrose were hypothesized to predict escalation of fentanyl intake. Rats underwent daily 1-h acquisition sessions for i.v. fentanyl self-administration (2.5 μg/kg; FR1) for 7 days, followed by 21 6-h escalation sessions, then tissue from prefrontal cortex was collected for RNA sequencing and qPCR. Latent growth curve and group-based trajectory modeling were used, respectively, to evaluate the association between sucrose reinforcement and fentanyl self-administration and to identify whether distinct escalation phenotypes can be linked to gene expression patterns. Results: Sucrose breakpoints were not predictive of fentanyl acquisition nor change during escalation, but did predict fentanyl intake on the first day of extended access to fentanyl. Permutation analyses did not identify associations between behavior and single gene expression when evaluated overall, or between our ascertained phenotypes. However, weighted genome correlation network analysis (WGCNA) and gene set enrichment analysis (GSEA) determined several gene modules linked to escalated fentanyl intake, including genes coding for voltage-gated potassium channels, calcium channels, and genes involved in excitatory synaptic signaling. Transcription factor analyses identified EZH2 and JARID2 as potential transcriptional regulators associated with escalated fentanyl intake. Genome-wide association study (GWAS) term categories were also generated and positively associated with terms relating to substance use disorders. Discussion: Escalation of opioid intake is largely distinct from motivation for natural reward, such as sucrose. Further, the gene networks associated with fentanyl escalation suggest that engagement of select molecular pathways distinguish individuals with "addiction prone" behavioral endophenotypes, potentially representing druggable targets for opioid use disorder. Our extended in silico identification of SNPs and transcription factors associated with the "addiction prone" high escalating rats highlights the importance of integrating findings from translational preclinical models. Through a precision medicine approach, our results may aid in the development of patient-centered treatment options for those with OUD.

Identifiers

PMID39713469
PMCPMC11661085

What OpenQuestion holds

Textmetadata
LicenceCC BY-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.